Literature DB >> 15122702

Expression of CCR7 in multiple sclerosis: implications for CNS immunity.

Pia Kivisäkk1, Don J Mahad, Melissa K Callahan, Keith Sikora, Corinna Trebst, Barbara Tucky, Jerome Wujek, Rivka Ravid, Susan M Staugaitis, Hans Lassmann, Richard M Ransohoff.   

Abstract

It is unclear how immune cells traffic between the lymphoid compartment and the central nervous system (CNS), which lacks lymphatic vessels and is shielded by the blood-brain barrier. We studied the expression of CCR7, a chemokine receptor required for migration of T cells and dendritic cells (DCs) to lymphoid organs, in the CNS of patients with multiple sclerosis (MS) to gain insight into pathways for CNS immune cell trafficking. Inflamed MS lesions contained numerous CCR7+ myeloid cells expressing major histocompatibility complex class II, CD68 and CD86, consistent with maturing DCs. CCR7+ DCs also were identified in cerebrospinal fluid (CSF). These observations suggested that the afferent limb of CNS immunity is comprised, in part, of DCs, which are generated within the CNS and migrate to deep cervical lymph nodes through the CSF after antigen capture. Ninety percent of CSF T cells expressed CCR7 and CSF from patients with MS was relatively depleted of CCR7-negative effector-memory T cells. In contrast, all T cells in parenchymal MS lesions lacked CCR7, indicating local retention and differentiation of central-memory T cells upon restimulation by antigen within the CNS. These data suggested that the efferent limb of CNS immunity is executed by central-memory T cells, which enter CSF directly from the circulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122702     DOI: 10.1002/ana.20049

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  102 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.

Authors:  Benjamin D Clarkson; Erika Héninger; Melissa G Harris; JangEun Lee; Matyas Sandor; Zsuzsanna Fabry
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 3.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 4.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

5.  Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.

Authors:  N Schwab; J C Ulzheimer; R J Fox; T Schneider-Hohendorf; B C Kieseier; C M Monoranu; S M Staugaitis; W Welch; S Jilek; R A Du Pasquier; W Brück; K V Toyka; R M Ransohoff; H Wiendl
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

Review 6.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

7.  Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases.

Authors:  Alla L Zozulya; Emily Reinke; Dana C Baiu; Jozsef Karman; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

Review 8.  Central nervous system drug development: an integrative biomarker approach toward individualized medicine.

Authors:  B Gomez-Mancilla; E Marrer; J Kehren; A Kinnunen; G Imbert; R Hillebrand; M Bergström; M E Schmidt
Journal:  NeuroRx       Date:  2005-10

9.  Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Authors:  M W Pennington; C Beeton; C A Galea; B J Smith; V Chi; K P Monaghan; A Garcia; S Rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Journal:  Mol Pharmacol       Date:  2009-01-02       Impact factor: 4.436

Review 10.  Pro-cognitive properties of T cells.

Authors:  Jonathan Kipnis; Sachin Gadani; Noël C Derecki
Journal:  Nat Rev Immunol       Date:  2012-08-20       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.